Mark is a pioneer in the use of genetically modified mice for pharmaceutical and basic research. He has worked in immunology, oncology, animal model construction and gene editing. Before joining GemPharmatech, Dr. Moore was a co-founder and CSO of Deltagen, the first high-throughput gene KO and target development company, and later served as the Executive Director of the International Mouse Phenotyping Consortium (IMPC). He received his Ph.D. in Biology from Brandeis University studying antibody gene recombination using transgenic mice.
Dr. Xu has extensive experience in business formation and management, technology R&D, intellectual property (IP) development and commercialization. Prior to GemPharmatech, Dr. Xu has been managing technology and IP development and commercialization at multiple companies in the fields of Biotechnology, Nanotechnology, drug discovery, cell-based cancer therapeutics and diagnostic devices. Dr. Xu received his Ph.D. in Molecular Biology from Duesseldorf University, conducted his Postdoc research at the University of Pennsylvania, School of Medicine and is a current member of American Intellectual Property Law Association (AIPLA).
Dr. Li is a neuroscientist by training with Dr V.N. Murthy and received her doctoral degree from Harvard University. She conducted postdoctoral research with Dr. J.M. Friedman at Rockefeller University. She joined Taconic Biosciences in 2017, providing scientific support to both commercial products and scientific services. Zhiying joined GemPharmatech in 2020. She is a firm believer in ethical use of research animals and their invaluable contribution to biomedical research for the benefit of human health.